brcaness profile of sporadic ovarian cancer predicts disease recurrencebrcaness散发性卵巢癌预测疾病的复发.pdf
文本预览下载声明
BRCAness Profile of Sporadic Ovarian Cancer Predicts
Disease Recurrence
1,2 3 4 2 3
Weiya Z. Wysham , Paulette Mhawech-Fauceglia , Hong Li , Laura Hays , Suzanna Syriac , Tijana
5 1 1,2 2,6 1,2
Skrepnik , Jay Wright , Nupur Pande , Maureen Hoatlin , Tanja Pejovic *
1 Department of Obstetrics and Gynecology, Oregon Health Science University, Portland, Oregon, United States of America, 2 Knight Cancer Institute, Portland, Oregon,
United States of America, 3 Department of Pathology, Roswell Park Cancer Institute, Buffalo, New York, United States of America, 4 Department of Biostatistics, Oregon
Health Science University, Knight Cancer Institute, Portland, Oregon, United States of America, 5 University of Arizona, Tucson, Arizona, United States of America,
6 Department of Biochemistry and Molecular Biology, Oregon Health Science University, Portland, Oregon, United States of America
Abstract
Background: The consequences of defective homologous recombination (HR) are not understood in sporadic ovarian
cancer, nor have the potential role of HR proteins other than BRCA1 and BRCA2 been clearly defined. However, it is clear
that defects in HR and other DNA repair pathways are important to the effectiveness of current therapies. We hypothesize
that a subset of sporadic ovarian carcinomas may harbor anomalies in HR pathways, and that a BRCAness profile (defects in
HR or other DNA repair pathways) could influence response rate and survival after treatment with platinum drugs. Clinical
availability of a BRCAness profile in patients and/or tumors should improve treatment outcomes.
Obj
显示全部